In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Becton Dickinson's Magic Markers

Executive Summary

Becton Dickinson thinks the continued automation of diagnostics is a no-win, low-margin game. Instead, it's making a big bet on discovering new, proprietary tests. And while the gamble is both high-cost and high-risk, the company figures the drug industry has now funded enough infrastructure and genomic research to make BD's search affordable. One other gamble: BD will have to partner out much of what it discovers since it doesn't have all the requisite testing platforms on which to run the assays.
Advertisement

Related Content

BD's Challenge: Making Everything Old New Again
BD's Progress in Molecular Markers
Big Diagnostics Companies See the Genomics Light
Beckman Coulter's Play for High Growth

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel